FDA Approves Optune Lua® as First-of-its-Kind Treatment for Metastatic Non-Small Cell Lung Cancer Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved Optune Lua®, a…
At Lenovo Tech World, Lenovo™, in collaboration with Innovations in Dementia, launched “Alzheimer’s Intelligence,” a photorealistic 3D avatar powered by AI, designed to support individuals and families affected by dementia…
Heidelberg Engineering, a leading provider of ophthalmic imaging and healthcare data solutions, has announced that the FDA has granted clearance for its SPECTRALIS® Flex Module. This advanced, multimodal imaging platform…
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global leader in eye health, has announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ intraocular lens (IOL). This…
Supergut, the first clinically validated nutrition brand for gut health, is now available at Target stores across the U.S. and online at Target.com. The brand’s exclusive Target lineup features its…
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a new research collaboration with Hanmi Pharmaceutical, a prominent biopharmaceutical company in Korea. The partnership aims to identify…
Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to felzartamab, an investigational anti-CD38 monoclonal antibody. This…
GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory…
Veterinary technicians play a vital role in the veterinary field, carrying out important tasks such as assisting in surgeries, conducting diagnostic tests, and providing emergency care. To meet the increasing…
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor,…
Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…